- Alcohol-Linked Liver Deaths Rising in Women and Young Adults
- More Than 460 CDC Workers Reinstated After Layoffs
- Former MTV Host Ananda Lewis Dies at 52 After Breast Cancer Battle
- Lack Of Sleep Alters Teens’ Brains, Potentially Promoting Behavior Issues
- Microbiome Linked To Memory Issues, Dementia In Parkinson’s Patients
- Childhood Trauma Boosts Endometriosis Risk
- Mild Sleep Apnea More Common Among Female Athletes Than Thought
- ‘Forever Chemicals’ Linked To Elevated Childhood Blood Pressure
- CT Scans Outperform DNA Stool Tests In Colon Cancer Screening, Study Says
- RFK Jr. Installs Critics on Vaccine Recommendation Panel
Internal Tissue Adhesive Approved

The U.S. Food and Drug Administration has approved the first tissue adhesive for internal use.
Known as TissuGlu, surgeons can use the urethane-based adhesive to connect tissue flaps created during surgery to remove extra fat or skin, or to restore weak or separated abdominal muscles (abdominoplasty). The new adhesive may reduce or eliminate the need for surgical drains to remove fluid between such flaps, the agency said in a news release.
“The FDA’s approval of the first synthetic adhesive for internal use will help some abdominoplasty patients get back to their daily routine after surgery more quickly than if surgical drains had been inserted,” Dr. William Maisel, deputy director for science at FDA’s Center for Devices and Radiological Health, said in the news release.
The product was evaluated in a clinical trial of 130 people who had elective abdominoplasty, half of whom received TissuGlu with no surgical drains and half of whom received surgical drains. Among the TissuGlu group, 73 percent did not need any postoperative interventions to drain fluid, the FDA said.
TissuGlu is produced by Cohera Medical, based in Pittsburgh.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.